Lowey reintroduces sunscreen monograph bill
This article was originally published in The Tan Sheet
Executive Summary
Rep. Nita Lowey, D-N.Y., reintroduces the Skin Cancer Prevention, Education, and Consumer Right-To-Know Act April 23. The bill, H.R. 2088, would give FDA 180 days to finalize its long-awaited monograph for broad-spectrum sunscreen ingredients that protect consumers from both UVA and UVB rays. The legislation, similar to a bill Lowey introduced in the previous Congress, would also require the Department of Health and Human Services to initiate a nationwide education campaign on the importance of sunscreen application (1"The Tan Sheet" Dec. 15, 2008, p. 12). The legislation was referred to the House Energy and Commerce Committee
You may also be interested in...
Dodd reintroduces sunscreen monograph bill
Dr. Reddy' creating group of about 30 scientists to focus on proprietary product development, responsible for building the branded R&D portfolio in collaboration with partners and service providers.Sen. Chris Dodd, D-Conn., reintroduces legislation imposing a 180-day deadline on FDA to finalize the monograph for broad-spectrum sunscreen ingredients that shield UVA and UVB rays (see story p. 10). The Sunscreen Labeling Protection Act, S. 1112, co-authored by Rhode Island Democrat Jack Reed, was referred May 20 to the Health, Education, Labor and Pensions Committee. Rep. Nita Lowey, D-N.Y., in April reintroduced a House
Congresswoman, Pageant Winner Back Petition For Final Sunscreen Regs
A consumer advocacy group gets support from a member of Congress and a beauty pageant winner as well as industry stakeholders for its citizen petition to light a fire under FDA about making state-of-the-art, broad-spectrum sunscreens available in the U.S
Speculation Over Moderna Vaccine Deal With Tata, Wockhardt
Moderna is speculated to be in talks with Indian firms, including Wockhardt and a Tata group company, for manufacturing its COVID-19 vaccine. A deal in India could help the company meet its obligation to supply COVAX but Moderna is likely to choose its partner carefully.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: